1-(Methoxymethyl)cyclobutane-1-carbonitrile

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-(Methoxymethyl)cyclobutane-1-carbonitrile
• 英文别名: 1-(methoxymethyl)cyclobutane-1-carbonitrile
• 化学式: C₇H₁₁NO
• 分子量: 125.17
• InChiKey: KNFQUIAEHPLNEH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  33
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOF<br/>[FR] COMPOSÉS PONTÉS EN TANT QU'INHIBITEUR ET DÉGRADEUR DE KRAS G12D ET LEUR UTILISATION
  申请人：BEIGENE LTD

  公开号：WO2022148422A1

  公开（公告）日：2022-07-14

  Provided herein are Bridged Compounds having the following structures: (I) wherein R1a, R1b, R1c, R1d, R2a, R2b, R2c, R2d, R3a, R3b, R3c, R3d, R4, R5, R6, R7, R8, m1, m2, m3, n2, n3, n4, q, X1, X2, Y1, Y2, L1and ring A are as defined herein, compositions comprising an effective amount of a Bridged Compound, and methods for treating or preventing various diseases, e.g., pancreatic cancer, or a condition treatable or preventable by inhibition of the function of KRAS protein. In another aspect, a Bridged Compound is useful for treating or preventing a condition treatable or preventable by inhibition of the function of KRAS protein with G12D mutation. In another aspect, a Bridged Compound is useful for treating or preventing a condition treatable or preventable by inhibition of a RAS/MAPK pathway.

  本文提供了具有以下结构的桥接化合物：（I），其中R1a，R1b，R1c，R1d，R2a，R2b，R2c，R2d，R3a，R3b，R3c，R3d，R4，R5，R6，R7，R8，m1，m2，m3，n2，n3，n4，q，X1，X2，Y1，Y2，L1和环A的定义如本文所述，包含有效量的桥接化合物的组合物，以及用于治疗或预防各种疾病的方法，例如胰腺癌或可通过抑制KRAS蛋白功能来治疗或预防的疾病。在另一个方面，桥接化合物可用于治疗或预防可通过抑制具有G12D突变的KRAS蛋白功能来治疗或预防的疾病。在另一个方面，桥接化合物可用于治疗或预防可通过抑制RAS / MAPK途径来治疗或预防的疾病。
• PYRIDINYL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF AS AOC3 INHIBITORS
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP3455216B1

  公开（公告）日：2020-11-04
• MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE
  申请人：AbbVie Inc.

  公开号：EP3668504A1

  公开（公告）日：2020-06-24
• Pyridinyl derivatives, pharmaceutical compositions and uses thereof
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20170327483A1

  公开（公告）日：2017-11-16

  The invention relates to new pyridinyl derivatives of the formula wherein R 1 and A are as defined in the description and claims, to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.
• LSD1 INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF
  申请人：MEDSHINE DISCOVERY INC.

  公开号：US20200345700A1

  公开（公告）日：2020-11-05

  A cyclopropylamine compound as a lysine-specific demethylase 1 (LSD1) inhibitor. Particularly, the present invention relates to a compound represented by formula (I) and a pharmaceutically acceptable salt thereof. The present invention also provides an application of the same in preparing a drug for treating an LSD1-related disease.